Focal macular electroretinograms after photodynamic therapy combined with posterior juxtascleral triamcinolone acetonide

Kohei Ishikawa, Hiroaki Nishihara, Shinsuke Ozawa, Chang Hua Piao, Yasuki Ito, Mineo Kondo, Hiroko Terasaki

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

PURPOSE: Retinal function is commonly depressed transiently after photodynamic therapy (PDT). Additional treatment may prevent this impaired retinal function. The purpose of this study was to determine the changes in the focal macular electroretinograms (FMERGs) after PDT combined with TA for age-related macular degeneration. METHODS: Thirty-four eyes that were successfully treated by PDT with a posterior juxtascleral injection of TA were studied. FMERGs, optical coherence tomography, and indocyanine green angiography were performed before and after the PDT. RESULTS: The mean amplitudes of the FMERGs were not significantly decreased 1 week after PDT with TA (P > 0.05). The mean ratio of the FMERG b-wave 1 week after PDT to that before PDT was 1.09, with an indistinct hypofluorescence at the site of the PDT (18 eyes), and the ratio was 0.91 in the eyes with a distinct hypofluorescence border (16 eyes; P < 0.05). CONCLUSION: The combined use of TA with PDT mitigated the depression of retinal function soon after PDT. However, there were cases of severe choroidal hypoperfusion corresponding to the site of the laser spot that impaired retinal function in comparison to cases with mild hypoperfusion. Even with severe choroidal hypoperfusion, the deterioration in retinal function was relatively mild, with the b-wave FMERG reduced by only 10%.

Original languageEnglish
Pages (from-to)803-810
Number of pages8
JournalRetina
Volume29
Issue number6
DOIs
Publication statusPublished - 06-2009
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Fingerprint

Dive into the research topics of 'Focal macular electroretinograms after photodynamic therapy combined with posterior juxtascleral triamcinolone acetonide'. Together they form a unique fingerprint.

Cite this